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Bordetella pertussis is a Gram-negative bacterium and the causative agent of whooping 
cough. Whooping cough is currently re-emerging worldwide and, therefore, still poses 
a continuous global health threat. B. pertussis expresses several virulence factors that 
play a role in evading the human immune response. One of these virulence factors 
is virulence associated gene 8 (Vag8). Vag8 is a complement evasion molecule that 
mediates its effects by binding to the complement regulator C1 inhibitor (C1-INH). This 
regulatory protein is a fluid phase serine protease that controls proenzyme activation 
and enzyme activity of not only the complement system but also the contact system. 
Activation of the contact system results in the generation of bradykinin, a pro-inflammatory 
peptide. Here, the activation of the contact system by B. pertussis was explored. We 
demonstrate that recombinant as well as endogenous Vag8 enhanced contact system 
activity by binding C1-INH and attenuating its inhibitory function. Moreover, we show that 
B. pertussis itself is able to activate the contact system. This activation was dependent 
on Vag8 production as a Vag8 knockout B. pertussis strain was unable to activate the 
contact system. These findings show a previously overlooked interaction between the 
contact system and the respiratory pathogen B. pertussis. Activation of the contact 
system by B. pertussis may contribute to its pathogenicity and virulence.
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inTrODUcTiOn
Bordetella pertussis is the causative agent of whooping cough, also known as pertussis, a contagious 
disease of the respiratory tract that is re-emerging worldwide despite high vaccination coverage. To 
date, pertussis is still ranked in the top 10 most deadly childhood diseases posing a serious health 
problem (1). The acellular pertussis vaccine (ACV), used in many industrialized countries, protects 
against disease for up to 7 years while natural infection confers protection for up to 20 years (2, 3). 
Alarmingly, the ACV does not prevent transmission of the pathogen (4). For this reason, it is widely 
accepted that an improved pertussis vaccine is needed (5). In order to improve the pertussis vaccine, 
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it is of great importance to better understand the interactions 
between the respiratory pathogen B. pertussis and the immune 
system.
The contact system is a key player in innate immunity and 
is part of the coagulation system (6, 7). The contact system 
consists of the two proenzymes factor XII (FXII) and plasma 
prekallikrein and the cofactor high-molecular weight kininogen 
(HK). In vitro, the contact system is activated when FXII binds 
to a negatively charged surface and is autocleaved forming FXIIa 
that is further processed to βFXIIa (8). Lessons from human 
pathology imply that analogous processes may take place on the 
surface of vascular endothelial cells (9) or platelets (10). FXIIa 
cleaves plasma prekallikrein forming active plasma kallikrein 
(PK). Activation of this protease subsequently mediates the 
cleavage of HK and formation of the pro-inflammatory peptide 
bradykinin (BK) (11). BK release triggers endothelial perme-
ability resulting in vasodilation and infiltration of leukocytes 
(7). Activation and activity of the contact system is regulated by 
the 105 kDa complement regulator C1 inhibitor (C1-INH) (12), 
which inhibits the activity of β-FXIIa, α-FXIIa, and PK, by form-
ing covalent complexes with its target proteases (13). C1-INH 
consists of a C-terminal protease inhibiting serpin domain and 
an N-terminal domain that is predicted to be heavily O- and 
N-linked glycosylated. Besides being involved in contact system 
regulation, C1-INH is also the main inhibitor of the classical and 
lectin pathways of the complement system where it inactivates 
the respective proteases necessary for activation of the comple-
ment cascade (14). Interestingly, the interplay between B. per-
tussis and the contact system remains unexplored even though 
Escherichia coli and Salmonella (15), Streptococcus pyogenes, 
Bacillus stearothermophilus, Bacillus subtilis, Porphyromonas 
gingivalis, Pseudomonas aeruginosa, Serratia maracescens, as 
well as several Vibrio species (16) have been shown to activate 
this system.
B. pertussis produces multiple virulence factors involved 
in immune evasion (17). It was recently shown that virulence 
associated gene 8 (Vag8) of B. pertussis binds to C1-INH (18, 
19). Vag8 is a 95  kDa autotransporter. Autotransporters are 
typically processed into a channel and a passenger domain 
(20). The passenger domain will pass through the channel and 
can either remain attached to the bacterial membrane or be 
secreted into the bacterial surrounding (21). Autotransporter 
proteins, including Vag8, are also present on the surface of outer 
membrane vesicles (OMVs) that are secreted by Gram-negative 
bacteria (18, 22, 23). We have recently shown that secreted 
Vag8 binding to C1-INH away from the bacterial surface leads 
to complement evasion. This binding result in consumption of 
complement components C2 and C4 via uncontrolled cleavage 
by the proteases C1r, C1s, and MASP-2, away from the bacterial 
surface (18).
Since C1-INH controls both the complement and the contact 
system, we here investigated whether Vag8 influences contact 
system activity. We demonstrate that both recombinant and 
endogenously secreted Vag8 enhanced contact system activity by 
attenuation of the inhibitory function of C1-INH. Moreover, we 
show that B. pertussis effectively activated the contact system by 
producing Vag8.
MaTerials anD MeThODs
Bacterial strains and growth conditions
B. pertussis wild type B1917 strain (isolated in 2000), the isogenic 
Vag8 knockout strain B1917ΔVag8 (18), the B0442 strain pro-
ducing a mutated lipooligosaccharide (LOS) that was isolated in 
1954 (24) and the pertactin-deficient B4418 and B4374 strains 
as well as the pertactin-producing B4430 and B4393 strains 
isolated in 2016 were grown at 35°C, 5% CO2 on Bordet Gengou 
plates containing glycerol and 15% defibrinated sheep blood (BD 
Biosciences, Franklin Lakes, NJ, USA). After 3–5 days of culture, 
the bacteria were collected in buffer containing 50 mM HEPES, 
2 mM CaCl2, 50 µM ZnCl2, 0.02% NaN3, and 0.05% Tween-20 
(pH 7.35) further referred to as buffer A, the optical density was 
measured at 600 nm and bacteria were washed in buffer A. OMVs 
of both strains were prepared by ultracentrifugation as described 
previously (18, 25, 26).
recombinant Production of histidine-
Tagged (his-tag) Vag8 and the negative 
control Bordetella resistance to Killing  
a (Brka) Passenger Domain
Recombinant his-tag passenger domain of Vag8 was produced 
as previously described (18). BrkA was cloned using prim-
ers 5′-ATATGGATCCCAGGAAGGAGAGTTCGAC-3′ and 
5′-ATATGCGGCCGCCTACTGCAAGCTCCAGACATG-3′ 
(restriction sites underlined) and ligated into a modified 
pRSET-B vector containing a non-cleavable six residue his-tag 
(MHHHHHHGS) at the N-terminus of the protein as described 
previously (18, 27). BrkA was expressed and purified as Vag8 (18).
surface Plasmon resonance (sPr)
SPR was performed using a Biacore T200 (GE Healthcare, Little 
Chalfont, UK). Recombinant passenger domain of Vag8 was 
dissolved in 50  mM sodium acetate pH 5.0 and immobilized 
using primary amine coupling onto a CM5 sensor chip (GE 
Healthcare). All binding experiments were performed at 25°C 
in 10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% 
(v/v) surfactant P20. Increasing concentrations (2.5–160 nM) of 
either full length C1-INH (C1-INHFL, Complement Technology) 
or C1-INH containing only the serpin domain (C1-INHNT98) (28) 
were injected over the flow channels at 30 µL/min. Dissociation 
was allowed for 300  s followed by surface regeneration with 
10 mM glycine pH 2.5. BIAevaluation software (GE Healthcare) 
was used to analyze the data.
size exclusion chromatography With 
Multi-angle light scattering analysis 
(sec-Mals)
100 µL of protein samples were injected onto an S200 increase 
10/300 column (GE Healthcare) equilibrated in 50 mM Tris pH 
7.5, 150 mM NaCl and eluted with a flow rate of 0.4 mL/min. Light 
scattering and refractive index changes were measured using a 
Dawn Heleos-II light scattering detector and an Optilab-TrEX 
refractive index monitor respectively. Analysis was carried out 
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using ASTRA 6.1.1.175.3.4.14 software assuming a dn/dc value 
of 0.186 mL/g.
ethics
The study was conducted using blood donation from ±50 healthy 
adults for plasma collection and according to the principles 
expressed in the Declaration of Helsinki. Written informed consent 
was obtained from all blood donors before collection and samples 
were used anonymously. Approval was obtained from the medical 
ethics committee of the University Medical Centre Utrecht.
Plasma
Blood was collected in blood tubes containing sodium citrate 
(Vacuette tube, Greiner Bio-one, Kremsmünster, Austria) from 
±50 healthy volunteers after written informed consent. Following 
collection, samples were centrifuged twice at 2,000 g for 10 min 
and plasma of all donors was pooled. The pooled plasma was 
stored in aliquots at −80°C until use.
activation of the contact system: 
chromogenic substrate assay
To determine whether Vag8 could interfere with the inhibitory 
function of C1-INH on βFXIIa and PK, we made use of the 
chro mogenic substrate H-D-Pro-Phe-Arg-pNA (L-2120, Sigma 
(Merck), Darmstadt, Germany) that can be cleaved by both 
proteases (29). All experiments were performed in 96-well PVC 
flat-bottom microplate (Corning GmbH, Wiesbaden, Germany). 
Activation of the contact system in the presence of Vag8 and 
BrkA was first analyzed in a purified system. βFXIIa (33.3 nM 
corresponding to 1  µg/mL, Enzyme Research Laboratories, 
South Bend, Ind, USA) or PK (5.81 nM corresponding to 0.5 µg/
mL, Enzyme Research Laboratories) was pre-incubated with 
or without serum-derived C1-INH (95.2 nM corresponding to 
10 µg/mL, Complement Technologies, Tyler, TX, USA) that was 
pre-incubated for 10 min at 37°C with, Vag8, BrkA, buffer A (for 
βFXIIa), or phosphate buffered saline (PBS) (for PK). Activity 
was measured following the addition of 0.5 mM L-2120 (Bachem, 
Bubendorf, Switzerland) (29). Activation of the contact system in 
a more complex system was studied in citrated human plasma. 
For these experiments, 60% plasma was activated with βFXIIa 
(16.7 nM corresponding to 0.5 µg/mL) in the presence of PBS 
(buffer control), Vag8, BrkA (concentrations indicated in the 
figures), or OMVs obtained from the B. pertussis wild type strain 
B1917 or knockout strain B1917ΔVag8 (60 µg/mL) with 10 min 
pre-incubation at 37°C before addition of the chromogenic 
substrate L-2120. For maximum contact system activity, referred 
to as control, βFXIIa was added to the plasma at the same time 
as the addition of L-2120 ensuring that C1-INH did not have the 
chance to inhibit the contact proteases. The substrate conversion, 
referred to as kallikrein-like activity, was measured in a kinetic 
fashion up until 30 min (Figure S1 in Supplementary Material) 
and reported at the 10 min time point. Substrate conversion was 
measured with a microplate reader at 405 nm at 37°C over time 
(VersaMax microplate reader, Molecular Devices, Sunnyvale, 
CA, USA).
Activation of the contact system by B. pertussis was assessed 
by incubating B. pertussis wild type strain B1917 or knockout 
strain B1917ΔVag8 (3 × 107 CFU each) with 60% plasma or buffer 
A. Plasma incubated with βFXIIa (16.7  nM corresponding to 
0.5 µg/mL, Enzyme Research Laboratories) or only buffer A was 
taken along as positive and negative controls, respectively. These 
experiments were performed with 5 min pre-incubation at 37°C 
before addition of the substrate L-2120. Substrate conversion was 
measured at 37°C every 30 s with a microplate reader at 405 nm 
over time (PowerWave XS Microplate Spectrophotometer, 
BioTek, Winooski, VT, USA).
cleavage of hK: immunoblotting
To determine cleavage of HK in plasma in the presence of Vag8, 
βFXIIa (16.7  nM corresponding to 0.5  µg/mL) was added to 
90% plasma and incubated with either PBS or Vag8 (1,017 nM 
corresponding to 60 µg/mL) for 10 min at 37°C. Samples were 
diluted 40 times in reducing sample buffer (15.5% glycerol, 
96.8 mM Tris–HCl, 3.1% SDS, 0.003% bromophenol blue, and 
25 mM DTT), incubated for 10 min at 100°C and separated on 
a 10% SDS-PAGE gel. Proteins were blotted onto PVDF mem-
branes. Membranes were blocked with 4% skimmed milk in 
PBS containing 0.05% Tween (PBS-T) and washed with PBS-T 
three times for 10 min at 37°C between each incubation step. The 
immunoblot was subsequently incubated with a primary goat 
anti-human HK antibody (3 µg/mL final concentration, Affinity 
Biologicals, Ancaster, ON, Canada) overnight at 4°C and a sec-
ondary donkey-anti-goat-HRP antibody (0.5  µg/mL, Southern 
Biotech, Birmingham, AL, USA) mainly reacting with the HK 
light chain (30) for 2 h at 37°C. All antibodies were diluted in 1% 
skimmed milk in PBS-T. For detection, the Pierce ECL Western 
Blotting Substrate (Thermofisher Scientific, Waltham, MA, USA) 
was used and visualized using the ImageQuant (GE Life Sciences, 
Chicago, IL, USA).
For assessment of HK cleavage upon incubation of plasma 
with B. pertussis, several bacterial strains (2 ×  109  CFU) were 
incubated with 50% plasma either alone or in the presence of the 
contact protease inhibitors aprotinin (31) (100 units/mL, Sigma), 
which inhibits PK and d-phenylalanyl-prolyl-arginyl chlorome-
thyl ketone (32) (PPACK; 200  µM, Hematologic Technologies, 
Essex Junction, VT, USA), a multi-target serine protease inhibitor 
which restricts auto activation and self-digestion of FXIIa, and 
sampled after 30 min at 37°C shaking at 300 rpm. Plasma samples 
incubated with βFXIIa (16.7 nM corresponding to 0.5 µg/mL) or 
only buffer A were taken along as positive and negative controls, 
respectively. Samples were analyzed as described above.
statistical analyses
Statistical analyses were performed using GraphPad Prism 6.02 
and the differences between groups were analyzed for signifi-
cance using the two-tailed Student’s t-test. A p-value of ≤0.05 was 
considered statistically significant.
resUlTs
Vag8 attenuates the role of c1-inh as 
inhibitor of βFXiia and PK
It was recently shown that Vag8 binds to C1-INH using both ELISA 
and gel filtration chromatography (18, 19). In order to further 
FigUre 1 | Virulence associated gene 8 (Vag8) and complement regulator 
C1 inhibitor (C1-INH) interact to form a tight 1:1 complex. (a) Size exclusion 
chromatography with multi-angle light scattering analysis (SEC-MALS) of 
Vag8 (green), C1-INH (purple), and Vag8_C1-INH complex (blue). The 
masses calculated from the scattering are shown as lines across the peaks. 
Protein conjugate analysis demonstrates that the mass of complex (146 kDa) 
corresponds to 118 kDa of protein and 28 kDa of sugar. This is consistent 
with a 1:1 complex of Vag8 (60 kDa) and glycosylated C1-INH (58 kDa 
protein/28 kDa sugar). (B,c) SPR analyses of the binding between Vag8 on 
the chip surface and increasing concentrations of C1-INHFL (B) and 
C1-INHNT98 (c) in solution.
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characterize this interaction, we performed the combination of 
SEC-MALS on the individual proteins and the complex (Figure 1A). 
Both Vag8 and C1-INH behaved as monomers on the column. 
Addition of Vag8 to C1-INH shifted the elution position and calcu-
lation of the mass across the peak revealed that a 1:1 complex had 
been formed. We next performed SPR analysis to attempt to assess 
the affinity of the interaction (Figures 1B,C). Flowing increasing 
concentrations of C1-INHFL over Vag8 on the surface demonstrated 
clear binding. The almost non-existent off-rate of the interaction, 
combined with a slow enough on-rate that precluded reaching 
equilibrium, meant that we were unable to robustly calculate the 
KD of the interaction. However, attempts to fit the kinetics using a 
variety of binding models always produced KD values of 1 nM or 
lower, consistent with a tight interaction. In order to confirm that 
the interaction between Vag8 and C1-INH involved the serpin 
domain, we repeated the SPR with C1-INH lacking the N-terminal 
O-linked glycosylation domain. This construct interacted with Vag8 
with very similar kinetics to the full length protein (Figure 1C).
We have demonstrated that the binding of secreted Vag8 to 
C1-INH results in attenuation of the inhibitory effect of C1-INH 
leading to the cleavage of essential complement proteins away 
from the bacterial surface (18). Since C1-INH is also one of the 
main inhibitors of the contact system, we hypothesized that the 
interaction between C1-INH and Vag8 would have a similar effect 
on the activation of the contact system. To investigate the effect 
of Vag8 on the contact system, we first studied this in a purified 
system. Addition of Vag8 to purified βFXIIa and C1-INH resulted 
in a dose-dependent enhanced conversion of the chromogenic 
substrate. Addition of 10  µg/mL Vag8 (169.5  nM) is sufficient 
to completely neutralize C1-INH activity as comparable levels 
of activation as that of βFXIIa alone were reached (Figure 2A). 
This dose-dependent attenuation of inhibition by C1-INH was 
also observed upon the addition of Vag8 to a purified system 
containing PK and C1-INH (Figure  2B). A concentration of 
12.5 µg/mL Vag8 (203.4 nM) was sufficient to completely block 
the inhibitory capacity of C1-INH on PK activation. As a negative 
control we used BrkA. BrkA is another autotransporter protein of 
B. pertussis involved in complement evasion. BkrA has a similar 
structure and size as Vag8 and was produced in a similar way as 
Vag8 (33, 34). The inhibitory properties of C1-INH on βFXIIa 
and PK were not disturbed by the addition of BrkA at equimolar 
concentrations (Figure S2 in Supplementary Material). Taken 
together, Vag8 dose dependently attenuates the inhibitory effect 
of C1-INH on βFXIIa and PK in a purified system.
Vag8 enhances contact system activity in 
Plasma
Since we have shown that Vag8 can interfere with the regulatory 
activity of C1-INH on βFXIIa and PK in a purified system, we 
next assessed the effect of Vag8 in a more physiological setting. To 
this end, we incubated plasma either with buffer (pre-incubated 
plasma) or increasing concentrations of Vag8 in the presence of 
the contact system activator βFXIIa for 10 min before addition 
of the chromogenic substrate. This pre-incubation step is needed 
for C1-INH to inhibit the contact proteases βFXIIa and PK. 
Moreover, the chromogenic substrate was added immediately 
following βFXIIa addition (control plasma) indicating the 
FigUre 2 | Virulence associated gene 8 (Vag8) interferes with the inhibition of βFXIIa and plasma kallikrein (PK) by complement regulator C1 inhibitor (C1-INH).  
(a) Vag8 (2.5, 5, 7.5, 10, 12.5, 15, and 30 µg/mL) dose-dependently enhances the activity of 1 µg/mL βFXIIa in the presence of 10 µg/mL C1-INH reaching similar 
activity as βFXIIa alone upon using 10 µg/mL of Vag8. (B) Vag8 (2.5, 5, 7.5, 10, 12.5, 15, and 30 µg/mL) dose-dependently enhances the activity of 0.5 µg/mL PK in 
the presence of 10 µg/mL C1-INH reaching similar activity as PK alone upon using 12.5 µg/mL of Vag8. Data represent the mean ± SEM of three separate 
experiments. ***p ≤ 0.001, ****p ≤ 0.0001, ns = non-significant compared to the black bar.
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maximum kallikrein-like activity. Figure  3A shows that Vag8 
dose-dependently attenuates the inhibitory function of C1-INH 
thus enhancing the activation of the contact system, referred to 
as kallikrein-like activity. Comparable levels as control plasma 
are reached upon using 7.5 µg/mL of Vag8 (127.1 nM), with no 
significant difference between the control plasma and addition of 
30 µg/mL of Vag8 (508.5 nM). The negative control, BrkA, did not 
show any effect on contact system activity (data not shown). To 
determine whether endogenously secreted Vag8 is also capable 
of mediating this effect, OMVs derived from B. pertussis wild 
type strain B1917 or the knockout strain B1917ΔVag8 (18) were 
incubated with plasma and βFXIIa. We show that the OMVs 
derived from B. pertussis wild type strain B1917 were capable 
of attenuating the inhibitory function of C1-INH resulting in 
enhanced contact system activity to levels observed in control 
plasma conditions, whereas the OMVs obtained from the knock-
out strain B1917ΔVag8 were not (Figure 3B).
As previously mentioned, activation of the contact system ulti-
mately results in the cleavage of HK and the subsequent release of 
BK. Also clinically, cleavage of HK is related to BK production (30). 
To investigate the effect of recombinant Vag8 binding to C1-INH 
on HK cleavage in plasma, βFXIIa was incubated with plasma in 
the presence or absence of Vag8 and was assessed by immunob-
lotting to visualize HK cleavage. Figure 3C shows increased HK 
cleavage as indicated by the decreased intensity of the ~120 kDa 
full length HK band (30) in the presence of Vag8 compared to 
incubation with βFXIIa alone as well as by the detection of the 
~46 kDa cLC-HK chain. This is the cleaved L-chain which is often 
used as a marker of extensive contact system activation in plasma 
(35). In conclusion, we show enhanced contact system activity 
in the presence of recombinant and endogenous Vag8, which is 
most likely due to Vag8 binding to C1-INH and hence hampering 
the inhibitory properties of C1-INH on βFXIIa and PK.
B. pertussis activates the contact system 
Predominantly Through Vag8 Production
Although several bacteria are known to activate the contact 
system (15, 36–42), the interaction between B. pertussis and the 
contact system has not been investigated. As shown above, Vag8 
of B. pertussis hampers the inhibition of the contact proteases 
by binding C1-INH and hence enhances contact system activity 
(Figures  2 and 3). Next, we investigated whether B. pertussis 
itself can effectively activate the contact system. We show that 
B. pertussis wild type strain B1917 successfully activates the 
contact system in plasma as an increase in kallikrein-like activity 
was observed over time (Figure 4A). This activation was further 
examined by assessment of HK cleavage using immunoblot. 
Figure 4B shows a representative immunoblot in which degrada-
tion of the ~120 kDa full length HK and appearance of a ~46 kDa 
cLC-HK chain (30) was observed when B. pertussis strain B1917 
was added to the plasma. To verify that the observed HK cleav-
age was the result of contact system activation, aprotinin (31) 
and PPACK (32) were added to the B1917 samples to prevent 
FXIIa and PK activity. Figure 4B shows a lack of HK cleavage 
upon addition of both these inhibitors to plasma incubated with 
B. pertussis wild type strain B1917 indicating that the HK cleavage 
observed in the presence of this bacterium can be attributed to 
the activation of the contact system. Next, we assessed whether 
Vag8 production was responsible for the activation of the contact 
system by B. pertussis. Figure 4C shows the lack of HK cleavage 
in the presence of the B. pertussis knockout strain B1917ΔVag8 by 
immunoblot. Even after 180 min of incubation, no activation of 
the contact system by the B. pertussis knockout strain B1917ΔVag8 
was observed (data not shown). This is further supported by 
the decreased kallikrein-like activity shown upon incubating 
plasma with the B. pertussis knockout strain B1917ΔVag8 when 
compared to incubation with wild type strain B1917 (Figure 4D). 
FigUre 3 | Virulence associated gene 8 (Vag8) induces enhanced activation of the contact system in plasma. (a) 60% plasma was incubated with Vag8 (5, 7.5, 15, 
and 30 µg/mL) following 10 min pre-incubation with 0.5 µg/mL βFXIIa. Vag8 dose-dependently enhances the induced kallikrein-like activity reaching similar levels 
upon using 7.5 µg/mL of Vag8 as the maximum kallikrein-like activity observed by βFXIIa alone without pre-incubation. (B) Moreover, the kallikrein-like activity in 60% 
plasma was also enhanced in the presence of endogenous Vag8 on outer membrane vesicles (OMVs) (60 µg/mL) derived from the wild type Bordetella pertussis 
strain B1917 but not when using OMVs of the knockout strain B1917ΔVag8. (c) Enhanced contact system activation was also shown by immunoblot. 90% plasma 
was incubated with 0.5 µg/mL βFXIIa either in the presence of 60 µg/mL Vag8 or buffer for 10 min and analyzed using anti-high-molecular-weight-kininogen (HK). 
The presence of Vag8 results in increased cleavage of the ~120 kDa full length HK compared to βFXIIa alone and the detection of the ~46 kDa cLC-HK chain (note 
the second and third lane). Plasma alone at t = 0 (control) and without βFXIIa at t = 10 (buffer) showed no cleavage of HK. Data shown in panel (a) represent the 
mean ± SEM of three separate experiments, while panels B and c are representative of three separate experiments. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, 
****p ≤ 0.0001, ns, non-significant compared to the black bar.
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Moreover, we show that contact system activation is not restricted 
to B. pertussis strain B1917. Incubation of plasma with the LOS-
mutant B0442 as well as clinical strains either producing (B4430 
and B4393) or not producing pertactin (B4418 and B4374) also 
shows contact system activation as indicated by the detection of 
the ~46 kDa cLC-HK chain (Figure 5). In summary, B. pertussis 
is capable of activating the contact system as demonstrated by the 
observed kallikrein-like activity as well as by the cleavage of HK 
detected by immunoblot. We show that this is mainly depend-
ent on the production of the autotransporter Vag8, which will 
bind to C1-INH and thus attenuate its inhibitory function, as the 
B. pertussis knockout strain B1917ΔVag8 showed no HK cleavage 
and decreased kallikrein-like activity compared to its isogenic 
wild type strain B1917.
DiscUssiOn
Recently, we unraveled the mechanism responsible for secreted 
Vag8-mediated complement evasion (18). We showed that bind-
ing of secreted Vag8 to C1-INH resulted in the release of the active 
proteases C1s, C1r, and MASP-2 since C1-INH could no longer 
bind and thus inhibit their proteolytic activity. The presence of 
active C1s, C1r, and MASP-2 proteases in the serum resulted in 
the degradation of the complement proteins C4 and C2 away from 
the bacterial surface (18). We suggest that B. pertussis uses this 
complement evasion strategy to aid in the prevention of opsoni-
zation and complement-mediated lysis. Vag8 is not only secreted 
but also present on the bacterial surface where it binds to C1-INH 
(19, 43). Binding of C1-INH to the bacterial surface could also 
result in the inhibition of complement activation which has been 
shown for other bacteria such as Borrelia recurrentis (44). The 
contact system is another innate immune component consisting 
of proteases (11). Here, we show that in addition to interacting 
with the complement system (18), Vag8 of B. pertussis induced 
enhanced activation of the contact system as demonstrated by 
increased contact system activity and HK cleavage. We propose 
that Vag8 mediates activation of the contact pathway by binding 
to C1-INH and attenuating its inhibitory function as we have 
previously shown for its effect on the complement system (18). 
C1-INH is the predominant fluid phase inactivator of FXIIa and 
PK. This serpin inactivates these proteases by irreversibly bind-
ing to them resulting in conformational changes that disrupt the 
active site of the target proteases (13). This process is hampered 
in the presence of Vag8, which we expect to bind to C1-INH, 
and consequently interfere with the protease inhibition allow-
ing for enhanced activation of the contact system (illustrated 
in Figure 6). As activation of the contact system by bacteria is 
often induced by membrane-bound components (16), Figure 6 
depicts the activation of the contact system on the bacterial 
surface. However, we cannot exclude that activation occurs both 
on the surface as well as in fluid phase. Our results indicate that 
blockage of protease inhibition is essential for B. pertussis wild 
type strain B1917 induced activation of the contact system as 
in the absence of Vag8, C1-INH is free to inhibit the contact 
system proteases and, therefore, activation of the contact system 
is not induced (Figure 3). Whether B. pertussis can also interact 
with the PK inhibitor alpha-2-macroglobulin (45) remains to be 
investigated.
Here we show for the first time that B. pertussis can activate the 
contact system, which as a bacterium is not unique (15, 36–42). 
Other bacteria have been shown to activate this system via 
polyphosphates, which are present on E. coli, Vibrio cholerae, 
FigUre 4 | Bordetella pertussis activates the contact system mainly by Virulence associated gene 8 (Vag8) production. (a) B. pertussis wild type strain B1917 
(3 × 107 CFU) induces similar kallikrein-like activity in 60% plasma compared to addition of 0.5 µg/mL βFXIIa. (B) Contact system activation by B. pertussis wild type 
strain B1917 was also shown by immunoblot. 50% plasma was incubated for 60 min with B. pertussis wild type strain B1917 (2 × 109 CFU) alone or in combination 
with the contact system inhibitors d-phenylalanyl-prolyl-arginyl chloromethyl ketone (PPACK) or aprotinin and analyzed using anti-high-molecular-weight-kininogen 
(HK). Incubation with B. pertussis wild type strain B1917 resulted in almost complete cleavage of the ~120 kDa full length HK as indicated by the appearance of the 
~46 kDa cLC-HK chain. This feature was not observed in the presence of the inhibitors. (c) To determine whether Vag8 production was involved in contact system 
activation by this pathogen, 50% plasma was incubated either with B. pertussis wild type strain B1917 or with the knockout strain B1917ΔVag8 (2 × 109 CFU) and 
analyzed using anti-HK. The B. pertussis knockout strain B1917ΔVag8 was unable to activate the contact system as no cleavage of the ~120 kDa full length HK 
was detected. (D) This was also shown by the decreased kallikrein-like activity in 60% plasma upon incubation with the knockout strain B1917ΔVag8 (3 × 107 CFU) 
compared to the B. pertussis wild type strain B1917. Panels a–D are representative of three separate experiments.
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Corynebacterium diphtheria, and Haemophilus influenzae but 
also on B. pertussis (46, 47). Moreover, LPS present on Gram-
negative bacteria have been implicated in the activation of the 
contact system in  vitro (48, 49). Contact system proteins were 
furthermore shown to assemble on the bacterial surfaces of 
Salmonella typhimurium and E. coli resulting in the release of 
BK (15). An increase in BK at the site of infection may cause 
leakage of plasma and be beneficial for the bacteria as this will 
provide bacteria with nutrients (16). Nonetheless, BK triggers 
endothelial permeability resulting in infiltration of leukocytes 
(11). Moreover, cleavage of HK results in the generation of the 
antimicrobial peptide NAT-26 which could drive bacterial killing 
(38). Hence, whether activation of the contact system is beneficial 
or detrimental for the bacteria remains unclear. Contact system 
protein assembly on E. coli occurs on curli pili (42). As we do not 
observe HK cleavage in the presence of the B. pertussis knockout 
strain B1917ΔVag8, we expect that although the B. pertussis 
membrane-associated polyphosphates or LOS may trigger the 
contact system, attenuation of C1-INH via sequestration by Vag8 
is essential for full activation of this system. Alternatively, bacteria 
can express proteases that actively cleave contact system proteins 
such as staphopains of Staphylococcus aureus or streptokinase of 
S. pyogenes, which both cleave HK releasing BK (38, 50). B. pertus-
sis is unique in enhancing the activation of the contact system by 
producing a protein, Vag8, which inhibits the inhibitory function 
of the contact system regulator C1-INH.
FigUre 6 | Proposed mechanism for Virulence associated gene 8 (Vag8) 
mediated activation of the contact system. Vag8, either on the bacterial 
surface as part of an outer membrane vesicles (OMVs) or as the secreted 
passenger, binds to complement regulator C1 inhibitor (C1-INH) (left panel). 
This results in the lack of inhibition of the contact system proteases FXIIa and 
plasma kallikrein (PK) by C1-INH. The lipooligosaccharide and 
polyphosphates present on the outer membrane of Bordetella pertussis are 
most likely responsible for FXII activation on the bacterial membrane as has 
been shown for other bacteria (15, 36–42). This activation, which cannot be 
inhibited by C1-INH as it is bound to Vag8, will result in the release of 
bradykinin (BK). In the absence of Vag8, C1-INH will inhibit FXIIa and PK 
when formed and high-molecular-weight-kininogen (HK) will remain intact 
away from the bacterial surface (right panel).
FigUre 5 | Various Bordetella pertussis strains activate the contact system. 
Contact system activation by B. pertussis strains B0442, B4418, B4430, 
B4393, and B4374 was shown by immunoblot. 50% plasma was incubated 
for 60 min with the B. pertussis strains (2 × 109 CFU) and analyzed using 
anti-high-molecular-weight-kininogen (HK). Incubation with all the B. pertussis 
strains resulted in cleavage of the ~120 kDa full length HK as indicated by the 
appearance of the ~46 kDa cLC-HK chain.
8
Hovingh et al. Vag8 and the Contact System
Frontiers in Immunology | www.frontiersin.org June 2018 | Volume 9 | Article 1172
Infection with B. pertussis results in the disease whooping 
cough, which is typically associated with fits of coughs (or 
paroxysms) followed by a typical high-pitched whoop. These 
coughing fits generally persist weeks after the bacterium has 
been cleared and contribute greatly to the morbidity caused by 
this disease (51). To date, it is not completely understood what 
causes this type of cough. The persistence of a chronic cough in 
the absence of a stimulus is not unique to pertussis but has also 
been observed in patients on angiotensin converting enzyme 
inhibitors (ACEi) that are being treated for hypertension (32). 
ACE, which is produced by lung endothelial cells, breaks down 
BK (52). The cough associated with ACEi often remains for 
several days or weeks after the patients have withdrawn from 
taking the drug. Although the mechanism of ACEi-induced 
cough remains unresolved, there are indications that BK, of 
which the levels are increased during ACEi treatment, might be 
involved (53). The contact system is not only present in plasma 
but also in the lungs (54) and respiratory administration of BK 
to guinea pigs but also humans evokes a paroxysmal cough 
much like the cough associated with pertussis (55). In guinea 
pigs, this cough was shown to be induced by BK activating the 
B2 receptors on the bronchopulmonary C-fibers (56). These 
receptors are also expressed in humans on epithelial cells, fibro-
blasts, and endothelial cells of the bronchial lamina propria 
(57). It is likely that B. pertussis infection results in increased 
levels of BK in the lungs as we have shown HK cleavage in 
the presence of B. pertussis wild type strain B1917 and BK is 
a cleavage product of HK. Consequently, we speculate that 
B. pertussis-induced activation of the contact system may be 
involved in the induction of pertussis-specific cough and thus 
transmission. Moreover, the activation of the contact system 
may also play a role in lung pathology. Lung lesions caused by 
an infection with S. typhimurium were shown to be prevented 
upon inhibition of the contact system in a rat model (40). Fatal 
B. pertussis infection is also characterized by lung lesions (58) 
and hence the increased BK levels in the lungs following an 
infection with B. pertussis may contribute to lung pathology. 
Further research needs to be conducted to really understand 
the role of the activation of the contact system on pertussis 
pathology.
In light of the re-emergence of pertussis, it has become evident 
that the development of a novel pertussis vaccine is necessary 
(5). One of the potential proteins that could be included in such 
a vaccine is Vag8. Vaccination with Vag8, which was previously 
only known as a complement evasion molecule of B. pertussis, 
has been shown to give rise to antibodies which protect mice 
from infection following a B. pertussis challenge (59). Moreover, 
Vag8-specific antibodies have been detected in pertussis patients 
indicating that Vag8 is produced by B. pertussis during human 
infection (60). Next to the proposed possibility of including 
Vag8 in a novel acellular pertussis vaccine, this protein is also 
a component of the OMV-based pertussis vaccine and the live 
attenuated BPZE1 vaccine that are currently being investigated 
(61, 62). Vag8 is highly present on OMVs of B. pertussis making 
up 34–50% of the total OMV proteins and can also be found on 
the bacterial membrane (18, 20, 23). Due to Vag8’s high abun-
dance on OMVs, presence on the outer membrane of B. pertussis 
and the protective effect of this protein as a potential vaccine 
antigen, the overactivation of the contact system described here, 
together with the degradation of essential complement protein 
described earlier (18) may have implications for the inclusion of 
Vag8 in novel pertussis vaccines. These side effects could include 
local C1-INH deficiency with consequences for complement 
and contact system mediated adverse reactions (63). Inhibition 
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of C1-INH could result in increased BK formation which may 
mediate increased inflammation at the site of vaccination. 
Moreover, consumption of complement proteins resulting in 
decreased complement activation following vaccination could 
have a negative effect on the induction of memory B-cells which 
are normally induced via interactions between C3d-tagged 
microorganisms or immune-complex antigens and complement 
receptor 2 (64, 65). It may be advisable to modify Vag8 before the 
potential inclusion of this antigen in novel pertussis vaccines in 
order to avoid side effects that could be induced by binding of 
Vag8 to C1-INH.
In conclusion, we show that Vag8 enhances contact system 
activity and is mainly responsible for the observed activation of 
the contact system induced by B. pertussis. We propose that this 
is the result of C1-INH binding by Vag8. This potent C1-INH 
inhibitor secreted by B. pertussis not only mediates complement 
evasion but also an overlooked interaction between the contact 
system and the respiratory pathogen B. pertussis that may con-
tribute to its pathogenicity and virulence.
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FigUre s1 | Substrate assay kinetics. Substrate conversion, referred to as 
kallikrein-like activity, was measured in a kinetic fashion up until 30 min.  
(a) 1 µg/mL βFXIIa was incubated alone or with 10 µg/mL complement regulator 
C1 inhibitor (C1-INH) alone or in combination with different concentrations of 
virulence-associated gene 8 (Vag8) (2.5, 5, 7.5, 10, 12.5, 15, and 30 µg/mL).  
(B) 0.5 µg/mL plasma kallikrein (PK) was incubated alone or with 10 µg/mL 
C1-INH alone or in combination with different concentrations of Vag8 (2.5, 5, 7.5, 
10, 12.5, 15, and 30 µg/mL). (c) 60% plasma was incubated with Vag8 (5, 7.5, 
15, and 30 µg/mL) following 10 min pre-incubation with 0.5 µg/mL βFXIIa. 
Incubation of plasma with βFXIIa alone either without or with pre-incubation 
served as a control. In the main text, substrate conversion is reported at the 
10 min time point. Data represent the mean of three separate experiments.
FigUre s2 | The negative control BrkA does not interfere with the inhibition of 
βFXIIa and plasma kallikrein (PK) by complement regulator C1 inhibitor (C1-INH). 
(a) Bordetella resistance to killing A (BrkA) (30 µg/mL) has no effect on the 
kallikrein-like activity of 1 µg/mL βFXIIa in the presence of 10 µg/mL C1-INH 
when compared to 1 µg/mL βFXIIa in the presence of 10 µg/mL C1-INH alone. 
(B) BrkA (30 µg/mL) has no effect on the kallikrein-like activity of 0.5 µg/mL PK in 
the presence of 10 µg/mL C1-INH when compared to 0.5 µg/mL PK in the 
presence of 10 µg/mL C1-INH alone. Data represent the mean ± SEM of three 
separate experiments.
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